Stockhub

Antisense Therapeutics Limited: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

18 August 2022

  • curprev 06:5606:56, 18 August 2022 >Paris 915 bytes +915 Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == Antisense Therapeutics Limited, a biopharmaceutical company, engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase II clinical trial for the treatment of multiple sclerosis, Duchenne Muscular Dystrophy, asthma, and other inflammatory indications. The company's product pipeline also includes ATL1103,..."
Retrieved from "https://stockhub.co/research/Antisense_Therapeutics_Limited"